Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Becton Dickinson ( (BDX) ) just unveiled an announcement.
On September 16, 2025, Becton Dickinson and its subsidiary BD Euro Finance entered into a third amended and restated credit agreement with Citibank and other lenders, providing a $2.75 billion senior unsecured revolving credit facility. This agreement, which can be extended up to $3.25 billion, will support the company’s general corporate purposes and includes specific financial covenants and conditions, potentially impacting the company’s financial strategy and flexibility.
The most recent analyst rating on (BDX) stock is a Buy with a $206.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Outperform.
Becton Dickinson’s overall stock score is driven by strong earnings call performance, highlighting revenue growth and strategic initiatives. However, financial performance and valuation present challenges, with declining profitability margins and a high P/E ratio. Technical indicators suggest mixed momentum, adding to the cautious outlook.
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
Becton Dickinson is a prominent player in the medical technology industry, known for its development and manufacturing of medical devices, laboratory equipment, and diagnostic products. The company focuses on advancing health by improving medical discovery, diagnostics, and the delivery of care.
Average Trading Volume: 2,560,054
Technical Sentiment Signal: Sell
Current Market Cap: $53.76B
For an in-depth examination of BDX stock, go to TipRanks’ Overview page.